Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 64 Publications

13 Customer Reviews

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Cells were cultured with the indicated concentrations of PLS-123, rapamycin (Granta519 0.002 μM, Mino 0.001 μM, Z138 0.005 μM), and their combination for 48 h. The results are expressed as the mean of relative activity and S.D. from triplicate cultures. The results are representative of at least three similar experiments.

    Int J Cancer, 2018, 142(1):202-213. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

    Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

  • Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

    Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

  • Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

    2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 MkfnR5l1d3SxeHnjJGF{e2G7 MWqxNEBvVQ>? NIfNWXk4OiCq MlfCSG1UVw>? MkTjVI91\W62aXH0[ZMh[2GvcITveIhm[2mwLXnu[JVk\WRiY4n0c5RwgGmlaYT5 NVPjOIh7OjR7MEC4O|M>
HT-29 M2LRemN6fG:2b4jpZ{BCe3OjeR?= MYOxNEBvVQ>? MWe3NkBp M{jUOWROW09? NYnleHg2WG:2ZX70bYF1\XNiZHnnbZRwgGmwLXnu[JVk\WRiY4n0c5RwgGmlaYT5 M{LiO|I1QTByOEez
HT-29 NIP3W5lEgXSxdH;4bYMhSXO|YYm= NYLJSW5nOTBibl2= NGDqfnM4OiCq NGnFPWlFVVOR NYKw[WNiWG:2ZX70bYF1\XNiNT3mcJVwem:3cnHjbYwucW6mdXPl[EBkgXSxdH;4bYNqfHl? NX33XHIyOjR7MEC4O|M>
PC3 M4TBSmtqdmG|ZTDBd5NigQ>? M4LUZ|ExOCCwTR?= MnfnNUBp MYjEUXNQ NIqyW|RRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhRDFyIH7NMi=> MmfINlE6Pzh4OEO=
PC3 NXXyWZRPU2mwYYPlJGF{e2G7 MnjQNVAxKG6P NYLjXW9KOSCq NGXHbXdFVVOR MYHEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NFntc24zOTl5OE[4Ny=>
PC3 NGDzfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlWyNU42KM7:TR?= MVKxJIg> M2j3XGROW09? NEnrcnRKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy|IIfpeIghUUN3MDDv[kA9OTBibl2= MlnvNlE6Pzh4OEO=
HEK293 MWDGeY5kfGmxbjDBd5NigQ>? M3fNZVExOCCwTR?= MlrQPEBp MWrEUXNQ MX;Jcohq[mm2czDUVGEucW6mdXPl[EBl\We{YXTheIlwdiCxZjDQ[INlPCC5aYToJGVEPTBib3[gOVAhdk1? MVSyNVU{QTNyMR?=
BT-20 MVrLbY5ie2ViQYPzZZk> NXLMS2tJOjBizszN M2fjVWROW09? MVXEc4V{KG6xdDDpcohq[mm2IH3UU3JEOiCmZYDlcoRmdnRicFHrWEBUPDd|IIDoc5NxcG:{eXzheIlwdg>? NXv0SWdCOjF|NUO1OVE>
U937 MnrERY51cWKjY4TldolidCCDc4PhfS=> NGjhNY42OCEQvF2= Mn7GOFghcA>? NFrwcFJFVVOR M{jIcWlv\HWlZYOgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KHerbHSgeJlx\SCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJHBpcWyjZHXsdIhq[S1zIFrSN|IhcW5iVUmzO{Bk\Wyucx?= MYiyNVE1OjFyNh?=
U937 MnrrRY51cWKjY4TldolidCCDc4PhfS=> MlLmOVAh|ryP MYq0PEBp M1rFb2ROW09? NUjB[5djTG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCPSWCgdJJwfGWrbj3k[YZq[2mnboSgUIVocW:wZXzsZUBxdmW3bX;wbIlt[SCMUkOyMVIhcW5iVUmzO{Bk\Wyucx?= NVnGdJp3OjFzNEKxNFY>
U937 MVnBcpRq[mGldHXybYFtKEG|c3H5 MnjyOVAh|ryP MUW0PEBp MY\EUXNQ MXnEc4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JGV{[2incnnjbIliKGOxbHmgTGIyODFiaX6gWVk{PyClZXzsdy=> M3m0VFIyOTR{MUC2
MCF-7 MVHBeZRweGijZ4mgRZN{[Xl? NV\sXIh5OzBibl2= MmPBOEBp NE\xfJZFVVOR MVfJcoR2[2W|IHH1eI9xcGGpeR?= NXWwcZBYOjByMkixN|Q>
U87MG NXnWc5lQU2mwYYPlJGF{e2G7 MYqxJO69VQ>? MlLpOkBp NG\PfpFFVVOR Mk[wVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25? NFTQS40yQTh2OESwOC=>
U87MG MXXLbY5ie2ViQYPzZZk> MVuxJO69VQ>? NWXvcXhZPiCq NVzHZ5I2TE2VTx?= MoC5VI91\W62bImgbY5pcWKrdIOgOGVDWDFqVEewLUBxcG:|cHjvdplt[XSrb36= MljuNVk5PDh2MES=
U87MG MkDQT4lv[XOnIFHzd4F6 MX:xJO69VQ>? MWq2JIg> MmPoSG1UVw>? MUnEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? MlPYNVk5PDh2MES=
U87MG MULLbY5ie2ViQYPzZZk> MWCxJO69VQ>? Ml65OkBp NHzLcZpFVVOR NIDJXXRFd2W|IH7veEBqdmirYnn0JHAuPEWEUEGoWFM4NzR4KTDwbI9{eGixconsZZRqd25? NWfPdmF2OTl6NEi0NFQ>
COS7 cells expressing EGFP-HDQ74/rheb MkHnRZV1d3CqYXf5JGF{e2G7 NI\O[mwxNjJizszN MWWyOEBp NULEeJZCTE2VTx?= M2rabWlv\HWlZYOgZZV1d3CqYXf5 M{fVNVE5OzlzOUS5
COS7 cells expressing EGFP-LC3 MVPBeZRweGijZ4mgRZN{[Xl? MVqwMlIh|ryP NHLURpozPCCq NUPIWYdGTE2VTx?= NXLJfWI4UW6mdXPld{BifXSxcHjh[5k> MXqxPFM6OTl2OR?=
H4 MV\GeY5kfGmxbjDBd5NigQ>? MUCwMlIh|ryP M4LSclI1KGh? NGr4SFRFVVOR M2nHUWlv[3KnYYPld{B1cGVicnH0bY8hd2ZibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFIhfG9ibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFEhcW5iaIXtZY4hUDRiY3XscJM> MkHwNVgxOjR3OES=
HeLa NWL6N3J2TnWwY4Tpc44hSXO|YYm= NW\2WW5GOTByIH7N NEXOOWo{PiCq MmHiSG1UVw>? M1HDW2lv\HWlZYOgSnJDKEt{MEm1VEwhXDJyOUjMMEBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> MnSwNVc2PjN|OEW=
HeLa MUfGeY5kfGmxbjDBd5NigQ>? MYOxNFAhdk1? NF\RU2Q{PiCq NX;MNZJ[TE2VTx?= MX7JcoR2[2W|IF\SRkBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> NUXJZ3VuOTd3NkOzPFU>
HeLa NWTkbYszTnWwY4Tpc44hSXO|YYm= MljHNVAxKG6P M4rlelM3KGh? NVTpWnVmTE2VTx?= MoWxTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u MnzMNVc2PjN|OEW=
SYF MVLGeY5kfGmxbjDBd5NigQ>? MUKxNFAhdk1? NXjGbY91OjRiaB?= MV;EUXNQ MVfJcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= NHSxXXAyPzV4M{O4OS=>
SYF MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXKNVAxKG6P NUPoO5U4OjRiaB?= M{DMdGROW09? NHPwZlhKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgV3lHKGOnbHzz M{HLelE4PTZ|M{i1
HEK293T MYTBcpRqfmm{YXygRZN{[Xl? M1jxOVEhdk1? NGPado01KGR? M{O4cWROW09? MYjJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhWjVid3n0bEBGSzVyIH;mJFAvOSCwTR?= M{G1VFE4PDh3NUCx
HEK293T NIfXVnVCdnSrdnnyZYwhSXO|YYm= NF7n[YcyKG6P M4rkWlQh\A>? MVXEUXNQ MYDJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhYDRid3n0bEBGSzVyIH;mJFAvOyCwTR?= MlvFNVc1QDV3MEG=
PBMC NYrxV5p6TnWwY4Tpc44hSXO|YYm= M17iSlEhdk1? MW[xOEBl MWDEUXNQ MmrPVoVlfWOnczDDR3I2KGSnboPpeJk> NVrKSWc4OTd2OEW1NFE>
PBMC NF25TW1HfW6ldHnvckBCe3OjeR?= M2\Te|Ehdk1? M13SUVE1KGR? M3fsRmROW09? MoXwSI9meyCwb4SgZYZn\WO2IFPYR3I1KGSnboPpeJk> NIrMWHEyPzR6NUWwNS=>
HEK293 cells NHrU[oxMcW6jc3WgRZN{[Xl? NWS3Vnk4PTBibl2= NWfue2llPDVibXnu NW\TSWkxTE2VTx?= M3;TTWlvcGmkaYTzJI1VV1Jia3nuZZNmKGGldHn2bZR6KHerdHigTWM2OCCxZjCwMlEhdk1? NV;kRmVjOTd|NUC5OVM>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MXrGeY5kfGmxbjDBd5NigQ>? NVz3fm5nOTByIH7N MlXzOEBp NXPVTmM1TE2VTx?= Mkj0TY5lfWOnczDseYNq\mW{YYPlJJBzd3SnaX6geJJidnNvc4DsbYNqdmdiaX6gSJJwe2:yaHnsZUBu\Wyjbn;nZZN1\XJiU{KgZ4VtdHNidILhcpNn\WO2ZXSge4l1cCCQLXz1Z{BidmRiQz3seYM> NGrMXHAyPzF{OEK2Ni=>
Human mixed lymphocyte MofOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDHOUBvVQ>? NYLMV2ZETE2VTx?= NYr2NG1UUUN3ME2xMlYhdk1w MnvCNVYyQDV6NkW=
Lewis rat lymph node cells MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYG1JO69VQ>? MVrEUXNQ M2PQRmlEPTB;Mj62JO69VQ>? NIe5S5YyPjF6NUi2OS=>
cells from the thymus of normal BALB/c mice NYPoNVhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkL1NVAhdk1? M2H2bFczKGh? MmjHSG1UVw>? MmD3TY5pcWKrdIOgcJlueGixcILvcIln\XKjdHnvckApVEGIKTD3bZRpKEmFNUCgc4YhOyCwTR?= M3nCfVExODJzOUS4
MRK-nu-1 NWnNOpBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfJWY1qUUN3ME2wMlg1PSCyTR?= MmS2V2FPT0WU
OCUB-M MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXGxeWV{UUN3ME21MlI1KHCP MlvsV2FPT0WU
SF539 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXScnhKSzVyPUGxMlYheE1? MmjtV2FPT0WU
ES4 NXPRbWhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf3TWM2OD1{MT61JJBO NUn4dnA6W0GQR1XS
RL95-2 Moi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\DfmtbUUN3ME2xNFcheE1? M3L3WHNCVkeHUh?=
LC-2-ad MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXRTWM2OD12MkOgdG0> MnP2V2FPT0WU
Daudi NUXCVXBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTR|NDDwUS=> MVLTRW5ITVJ?
NTERA-S-cl-D1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTnWoszUUN3ME20OFMheE1? M2TJTXNCVkeHUh?=
OS-RC-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTZ3MjDwUS=> M{O2WXNCVkeHUh?=
VA-ES-BJ M321Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[yNYRKSzVyPUeyN{BxVQ>? MW\TRW5ITVJ?
GR-ST NUOydYdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;CZXVuUUN3ME24OFYheE1? NFHXOYxUSU6JRWK=
SW872 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\TdGlEPTB;OES2JJBO M122[HNCVkeHUh?=
NOS-1 NVu0R5VQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj6d5RKSzVyPUi3NUBxVQ>? NEC5emxUSU6JRWK=
MC116 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDmTWM2OD17OEWgdG0> MXzTRW5ITVJ?
NCI-H1355 NGXmelNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHqW2ZKSzVyPUGuNFEhdk1? NUHYbWt3W0GQR1XS
RPMI-8226 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[yWmlEPTB;MT6xPUBvVQ>? NYXocolPW0GQR1XS
TE-15 NUXSTlJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTtPGVtUUN3ME2xMlM3KG6P MXzTRW5ITVJ?
Ramos-2G6-4C10 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH64U49KSzVyPUGuOFYhdk1? M2DuRnNCVkeHUh?=
KU812 M2PnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf1eFlwUUN3ME2yMlAyKG6P MVjTRW5ITVJ?
EW-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\wbmlEPTB;Mj6xO{BvVQ>? M3jLTnNCVkeHUh?=
KS-1 NIr4SWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17rcmlEPTB;Mj60OUBvVQ>? NHrVXIFUSU6JRWK=
SK-LMS-1 NFvKbZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDOWpVKSzVyPUKuOFkhdk1? MUHTRW5ITVJ?
TGBC1TKB MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[5NWlEPTB;Mj62PUBvVQ>? MUfTRW5ITVJ?
TE-6 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknuTWM2OD1{Lke3JI5O MoXxV2FPT0WU
ETK-1 NFj6dYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJwOEKgcm0> NIXablNUSU6JRWK=
BE-13 M2TLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPZU|dKSzVyPUKuPVkhdk1? M1G0[3NCVkeHUh?=
A3-KAW Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzEdolKSzVyPUKuPVkhdk1? NGXYU2hUSU6JRWK=
TE-10 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkX4TWM2OD1|LkOgcm0> NF31fVVUSU6JRWK=
DOHH-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT3W4hKSzVyPUOuN|Uhdk1? NXj1bppRW0GQR1XS
ES6 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTIS|JHUUN3ME2zMlQ{KG6P NGHqXZpUSU6JRWK=
OPM-2 NHq0d|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXGZWNWUUN3ME20MlE2KG6P MUfTRW5ITVJ?
SH-4 NHzBb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjB[mNvUUN3ME20MlM1KG6P NWnLTnFuW0GQR1XS
NB13 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzNTWM2OD12LkO2JI5O MX7TRW5ITVJ?
HUTU-80 NUPqRlBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3XOJJ{UUN3ME20MlQzKG6P M3vBXHNCVkeHUh?=
CCRF-CEM Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLCe3NrUUN3ME20Mlk1KG6P M1TpSXNCVkeHUh?=
TGBC24TKB NFPZRohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjLdXpKSzVyPUWuOVEhdk1? M3vDfnNCVkeHUh?=
697 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID2c|JKSzVyPU[uNlghdk1? MkDJV2FPT0WU
J-RT3-T3-5 NWTybItET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jxT2lEPTB;Nj60OkBvVQ>? MVXTRW5ITVJ?
KALS-1 MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL0bGlKSzVyPU[uOVYhdk1? NXrRZXJ4W0GQR1XS
no-10 MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvjTWM2OD15LkK5JI5O NHvtXI1USU6JRWK=
SK-NEP-1 NHP6W21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfTTWM2OD16Lke5JI5O MUXTRW5ITVJ?
L-540 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTuT|duUUN3ME2xNE41OiCwTR?= NXXyNVRKW0GQR1XS
JiyoyeP-2003 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzUTWM2OD1zMD65OEBvVQ>? MY\TRW5ITVJ?
HH MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\HdGlEPTB;MUGuN|khdk1? Ml7vV2FPT0WU
SR NUnGSmRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnrSWllUUN3ME2xNU41PSCwTR?= NHz5eVBUSU6JRWK=
QIMR-WIL NH\rOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHT3UXZKSzVyPUGxMlg2KG6P NXS0eIJFW0GQR1XS
A4-Fuk NF7VT4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXWTWM2OD1zMz6xNkBvVQ>? MYPTRW5ITVJ?
CESS M4LHeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3KyXWlEPTB;MUOuNVMhdk1? NFvvcHFUSU6JRWK=
KE-37 NHfK[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjpfVhLUUN3ME2xOk4xPyCwTR?= MV7TRW5ITVJ?
SK-UT-1 NUPNWoRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUiwfXZuUUN3ME2xOk45OSCwTR?= MmnQV2FPT0WU
SIG-M5 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;VV|JkUUN3ME2xO{4zPSCwTR?= NV;BcY9jW0GQR1XS
HT MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XOXGlEPTB;MUeuOkBvVQ>? MY\TRW5ITVJ?
DEL M1zBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nvR2lEPTB;MUeuPVkhdk1? MVrTRW5ITVJ?
SK-PN-DW NW\jTog4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TCUWlEPTB;MkCuNlMhdk1? MWTTRW5ITVJ?
RPMI-8402 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTJzLke3JI5O MV\TRW5ITVJ?
RPMI-6666 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmq5TWM2OD1{ND60NkBvVQ>? NIfCWpFUSU6JRWK=
NCI-H720 NYPKXpRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvJTFVKSzVyPUK1MlQyKG6P NUTLZ|F2W0GQR1XS
EW-16 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDBTm1KSzVyPUK2Mlg4KG6P NUHRUVk{W0GQR1XS
BL-70 NH3seI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPVSWJWUUN3ME2yPE4{QCCwTR?= MnrJV2FPT0WU
SF126 NIK5NWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\MTWM2OD1|MD6zPEBvVQ>? NGLQdVZUSU6JRWK=
BC-1 NH61d4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFm1[YdKSzVyPUOxMlI3KG6P MkfjV2FPT0WU
MHH-PREB-1 MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mom4TWM2OD1|Mj60OEBvVQ>? M1nFNnNCVkeHUh?=
A101D MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTN{Lk[yJI5O MkjrV2FPT0WU
NMC-G1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Pr[2lEPTB;M{OuOlchdk1? MlPiV2FPT0WU
LB1047-RCC NFvtbIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTN2Lk[5JI5O NUHOWpBEW0GQR1XS
EM-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTFS2U6UUN3ME2zPE42OyCwTR?= MWjTRW5ITVJ?
COLO-684 NEDyO3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPBTWM2OD1|OT64JI5O M1XHXnNCVkeHUh?=
Becker NHrMbVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrSTWM2OD12MT6wOUBvVQ>? M3XmZXNCVkeHUh?=
BL-41 NIrDcWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTR|Lk[2JI5O NXPHNnhqW0GQR1XS
MDA-MB-134-VI NYPLWFQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjpWlFtUUN3ME20OE4xOiCwTR?= NIPtNIxUSU6JRWK=
L-363 MnrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnT3TWM2OD12ND63N{BvVQ>? Mn76V2FPT0WU
ECC4 NHm5XG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37BPGlEPTB;NESuO|ghdk1? NWX1ZW9xW0GQR1XS
A388 M{LUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\KcldVUUN3ME20OE45OiCwTR?= M4TGdnNCVkeHUh?=
HEL NHG0XIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTR7Lke5JI5O M2q4cHNCVkeHUh?=
RKO NYT0epBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3WTWM2OD13MD6yPUBvVQ>? M1Pjd3NCVkeHUh?=
KINGS-1 M3T1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTVzLkW1JI5O MoH1V2FPT0WU
EB-3 MkX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXtVG1LUUN3ME21Nk43PyCwTR?= NI[2Xm9USU6JRWK=
ARH-77 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvkTWM2OD13Mj64JI5O NXSze5g{W0GQR1XS
GCIY M3fHe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4e3b2lEPTB;NUOuOFYhdk1? M{DE[HNCVkeHUh?=
NCI-H1304 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H3bmlEPTB;NUeuNlIhdk1? NXXQdoJYW0GQR1XS
KARPAS-299 MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTkUYpKSzVyPU[xMlgzKG6P NUDaVlZ1W0GQR1XS
IA-LM MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTZ6LkGzJI5O MoHOV2FPT0WU
GI-1 M3fLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\kTWM2OD15MD6zPUBvVQ>? MY\TRW5ITVJ?
TE-11 NV3tT2toT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXTTWM2OD15Nz6xO{BvVQ>? MlfCV2FPT0WU
LS-411N MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTd5LkW3JI5O M1HVWHNCVkeHUh?=
no-11 NUKxZZRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvITWM2OD16Mz6yOEBvVQ>? MVXTRW5ITVJ?
MV-4-11 NF30eG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fXcmlEPTB;OEOuO|Mhdk1? Mnu1V2FPT0WU
BV-173 NF;oSZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIq3UnpKSzVyPUizMlk4KG6P MlPnV2FPT0WU
CMK NFnDZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTh2LkG2JI5O NWfPdYkxW0GQR1XS
LC4-1 NILJPYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTh4LkeyJI5O NWfxcYNmW0GQR1XS
COR-L279 M4LR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zPbmlEPTB;OEeuNlUhdk1? MnPpV2FPT0WU
NCI-H209 NF3mXHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrZZoZKSzVyPUi3MlQyKG6P MnPpV2FPT0WU
Raji M{PYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTh7LkeyJI5O NUfIelhQW0GQR1XS
LB996-RCC NYrVVoV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XRZmlEPTB;OUOuOFMhdk1? M1TKNnNCVkeHUh?=
NCI-H526 MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPkTWM2OD17Mz61PUBvVQ>? NWjhe2R5W0GQR1XS
KGN M3zodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTl4LkK5JI5O MWLTRW5ITVJ?
MOLT-4 NXL1T4RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jITGlEPTB;OU[uO|khdk1? MnfxV2FPT0WU
PF-382 MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzXUY5YUUN3ME25Ok44QSCwTR?= M2rwWXNCVkeHUh?=
BC-3 M1f4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPETWM2OD17OT6xPEBvVQ>? NYnnZ2RyW0GQR1XS
KARPAS-422 NFvYOJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTFyMj6wPUBvVQ>? MX;TRW5ITVJ?
SBC-1 NFvQSY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37ud2lEPTB;MUC3Mlc2KG6P Mn;WV2FPT0WU
LC-1F NVHsc5N4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTFyOD6wOUBvVQ>? NIXKcmdUSU6JRWK=
GB-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\VeoozUUN3ME2xNFkvODJibl2= NHXxSmNUSU6JRWK=
SNB75 Ml\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFzOT62PUBvVQ>? MkXZV2FPT0WU
BB65-RCC Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTFzOT65N{BvVQ>? M{XzeXNCVkeHUh?=
NCI-N87 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDKVZhKSzVyPUGyNU46QCCwTR?= NUTwRoxsW0GQR1XS
IST-MEL1 NF3ySFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTF{Mj6zPEBvVQ>? MWPTRW5ITVJ?
HOP-62 M3LtPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17kOmlEPTB;MUK2Mlg6KG6P NIfxOW9USU6JRWK=
ACN M2Owb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[zTWM2OD1zNE[uO|Uhdk1? M2nMd3NCVkeHUh?=
DMS-114 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTF3MD62O{BvVQ>? M2exV3NCVkeHUh?=
MLMA MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTF3OT64PEBvVQ>? NVfr[olwW0GQR1XS
HT-144 MnKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33mSWlEPTB;MU[1MlQ{KG6P Mof5V2FPT0WU
C2BBe1 M32zemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HJbmlEPTB;MU[3Mlc3KG6P NYPWRZZFW0GQR1XS
L-428 NUX1V5I3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF5Nz63JI5O NH\hO4FUSU6JRWK=
DU-4475 MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTF6Nz62PEBvVQ>? MnvFV2FPT0WU
CP67-MEL MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\xTWM2OD1zOUmuN|ghdk1? MV3TRW5ITVJ?
MEG-01 NX;ZdGFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWO1VItSUUN3ME2yNFEvQTZibl2= M3n0XHNCVkeHUh?=
IST-SL2 NU\tfnVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jqTGlEPTB;MkC4MlY{KG6P NGLWZYNUSU6JRWK=
ES8 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj4b|ZKSzVyPUKyOU46PCCwTR?= MkjMV2FPT0WU
COLO-800 NV\HeZJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlGyTWM2OD1{M{WuNlghdk1? NIPsclNUSU6JRWK=
MFH-ino MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPyTWM2OD1{M{WuPFQhdk1? NXjPeZFFW0GQR1XS
OVCAR-4 NITkdlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{niXWlEPTB;MkO3MlI1KG6P M{fU[XNCVkeHUh?=
PSN1 M4[ycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDXTWM2OD1{NEKuO|Ehdk1? NYi1XXoxW0GQR1XS
EW-12 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7v[YtKSzVyPUK0N{4yKG6P NYjxTWFoW0GQR1XS
HCC1599 NVHidHlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJ4MT60O{BvVQ>? M{KyOnNCVkeHUh?=
SJSA-1 M4C1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrxTWM2OD1{N{GuOFYhdk1? M3njNHNCVkeHUh?=
ST486 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PPT2lEPTB;Mkm2MlE1KG6P Mm\rV2FPT0WU
NOMO-1 M2r3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33jW2lEPTB;M{CwMlIyKG6P Mn3iV2FPT0WU
MN-60 NGKyWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fWbGlEPTB;M{C1MlMzKG6P NV30WHpJW0GQR1XS
HCC1187 MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\lTJlMUUN3ME2zNFcvOjVibl2= M2rKdXNCVkeHUh?=
SW982 M2fSZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfKPI9tUUN3ME2zNVQvPzVibl2= M4nsWXNCVkeHUh?=
LB647-SCLC NV3jV|NrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nt[WlEPTB;M{K4MlcyKG6P MYfTRW5ITVJ?
HC-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrpb5NXUUN3ME2zN|UvPSCwTR?= MX3TRW5ITVJ?
EHEB NYDZd3V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIH6RZpKSzVyPUOzO{42OiCwTR?= M3;vR3NCVkeHUh?=
TUR NHjBXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTN4Mz65OUBvVQ>? NGDMbFhUSU6JRWK=
LU-139 M{fVZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTN5OD6wNkBvVQ>? M4j1PXNCVkeHUh?=
NB1 MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH75W2xKSzVyPUO4OE41PSCwTR?= MULTRW5ITVJ?
BB30-HNC NF7RZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTN6OD6zNkBvVQ>? MUHTRW5ITVJ?
HAL-01 NGe1SnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LG[GlEPTB;M{i5MlI3KG6P MWLTRW5ITVJ?
K5 NGrP[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTRzMT6zO{BvVQ>? MUHTRW5ITVJ?
MZ2-MEL NH7mWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLWOplOUUN3ME20NVMvPjRibl2= M4L2PXNCVkeHUh?=
RXF393 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXCb41KSzVyPUSxOk41PSCwTR?= NFjo[4pUSU6JRWK=
NCI-H1648 M{TZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXue3dKSzVyPUSxO{42OyCwTR?= MVLTRW5ITVJ?
TE-12 NH\6e4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vMbGlEPTB;NEO0MlI3KG6P NV\pUGNKW0GQR1XS
EoL-1- NYfBXGRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nwfmlEPTB;NEO3Mlk5KG6P NXjTSVFXW0GQR1XS
JAR NXTnWmROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrEd4dMUUN3ME20N|gvPjJibl2= NV7KV2dbW0GQR1XS
DSH1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfKfGFKSzVyPUS1PE46OSCwTR?= M2jlZXNCVkeHUh?=
NCI-H187 NF[zU|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHUUGhjUUN3ME20OlIvQDFibl2= NW\4WmNxW0GQR1XS
HCE-4 MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorrTWM2OD12N{euOlYhdk1? MUnTRW5ITVJ?
8-MG-BA M1\YeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfRNWRLUUN3ME21PFEvPTJibl2= M3;6RXNCVkeHUh?=
KLE M{TpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTV6NT6yJI5O M4nXdXNCVkeHUh?=
KNS-42 M335U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4q1T2lEPTB;NUi2MlgyKG6P MoT3V2FPT0WU
MSTO-211H NI\tcm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXVTWM2OD14MEmuO|Qhdk1? MVrTRW5ITVJ?
GDM-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjVeXdKSzVyPU[xOE4xQSCwTR?= M{T0OHNCVkeHUh?=
TE-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjyTWM2OD14NE[uNVIhdk1? NF;CWIRUSU6JRWK=
BT-474 M1jYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvVSmJKSzVyPU[0O{4xPiCwTR?= NUO1[HNmW0GQR1XS
KARPAS-45 MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXq0ZmdiUUN3ME22OFcvPiCwTR?= NITFbFhUSU6JRWK=
MOLT-16 M33kZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jE[2lEPTB;NkS3Mlk{KG6P NWjLZpp[W0GQR1XS
KURAMOCHI MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHyS|lHUUN3ME22OVcvPTFibl2= Mm\iV2FPT0WU
K-562 NHjyO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j4[2lEPTB;Nk[5MlUyKG6P NX7rXYw4W0GQR1XS
EKVX MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLrTWM2OD14N{KuO|Ehdk1? M2rWOHNCVkeHUh?=
GAK NF:1XotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jCVGlEPTB;Nke1MlMhdk1? NIP4[lFUSU6JRWK=
NCI-SNU-5 NWizVXdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzITWM2OD14OUCuNFEhdk1? NYLvdZZlW0GQR1XS
NCI-H2126 M2mxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfUTWM2OD15Mk[uPFchdk1? MWLTRW5ITVJ?
CTV-1 NHzKdFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYr4clI1UUN3ME23OFQvQSCwTR?= MmS2V2FPT0WU
SW962 NWTvXWRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnqe3NQUUN3ME23OFgvPDRibl2= MWTTRW5ITVJ?
MONO-MAC-6 Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTrZZhUUUN3ME23OVYvQTNibl2= NXy4V4U{W0GQR1XS
NCI-H748 NVXXOW9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;NUGlEPTB;N{W4Mlk6KG6P MWDTRW5ITVJ?
NCI-H524 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTd6MD63N{BvVQ>? M2DTU3NCVkeHUh?=
LS-123 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O3[2lEPTB;N{m1MlY6KG6P M{T0e3NCVkeHUh?=
NB7 NHr4fVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRThzND6xOEBvVQ>? NYPCdVh7W0GQR1XS
LS-1034 NVuybFJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\LVYVKSzVyPUiyPE46QCCwTR?= M1fKXXNCVkeHUh?=
TE-5 M2fKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jzdmlEPTB;OEizMlU3KG6P MVTTRW5ITVJ?
A704 MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fZfWlEPTB;OEm5MlE2KG6P Mn;zV2FPT0WU
TK10 M1\Kd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;vNGFVUUN3ME25NVYvODNibl2= MoPVV2FPT0WU
NCI-H345 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH65WmFKSzVyPUm0N{4zOiCwTR?= NXPoNXJJW0GQR1XS
CGTH-W-1 M1zhbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\0TWM2OD17NEiuNVMhdk1? M3HBOXNCVkeHUh?=
NCI-H510A MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHiSmdSUUN3ME25PFUvOTJibl2= M2HwN3NCVkeHUh?=
NCI-H1963 NUL6cZNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWSyR5NqUUN3ME2xMlA{Ojl{IN88US=> M3zoW3NCVkeHUh?=
SCC-3 M4H4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf4cXZKSzVyPUGuNFM1OTRizszN NV3mUHY{W0GQR1XS
EW-11 NYXHNFVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDqXWU1UUN3ME2xMlA5PzR|IN88US=> NVq3cmZ3W0GQR1XS
CPC-N M2TRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvsVWZCUUN3ME2xMlA5QCEQvF2= NHvrO4VUSU6JRWK=
NCI-H1417 MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LlXGlEPTB;MT6xNlI3KM7:TR?= MVnTRW5ITVJ?
DG-75 NH3TdGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nRSGlEPTB;MT6xOlI5PSEQvF2= NYfMWng3W0GQR1XS
HD-MY-Z NIrrflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXUTWM2OD1zLkG2OFE3KM7:TR?= Ml2wV2FPT0WU
ATN-1 NUP4UYxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDtTWM2OD1zLkK2NlA6KM7:TR?= Mkm3V2FPT0WU
KM-H2 M2LEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ewTGlEPTB;MT6yOlQxQCEQvF2= NHjLWY1USU6JRWK=
NCI-H2081 M3OwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\adZFZUUN3ME2xMlI3PjN5IN88US=> NWXTO3NMW0GQR1XS
HL-60 M12xUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfGTWM2OD1zLkK2PVU6KM7:TR?= MVfTRW5ITVJ?
DB MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2j5OGlEPTB;MT6yO|I1OiEQvF2= MnrGV2FPT0WU
NCI-H1522 NVGx[|VRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvZPJpvUUN3ME2xMlI5QDh5IN88US=> MXXTRW5ITVJ?
AM-38 NH;Fe|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHGyNFlKSzVyPUGuN|A4OiEQvF2= M13DeXNCVkeHUh?=
NCI-H446 MkjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1THdmlEPTB;MT6zNlEzOSEQvF2= MVrTRW5ITVJ?
SU-DHL-1 NH\XWoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTBNHl{UUN3ME2xMlMzQDBzIN88US=> M3\MXnNCVkeHUh?=
NH-12 NGDYOpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLxbIY1UUN3ME2xMlM3Ozd2IN88US=> NUDobVZQW0GQR1XS
DMS-79 M{nvcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTZTWM2OD1zLkO2PFY3KM7:TR?= NXTGU402W0GQR1XS
NCI-H716 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFwM{i5PFYh|ryP MoDuV2FPT0WU
ML-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;iSJZKSzVyPUGuOFE2OjlizszN NFTobo5USU6JRWK=
NB10 M1zjU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3iyT2lEPTB;MT60OlY{OiEQvF2= MXLTRW5ITVJ?
ONS-76 NHPsWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmD3TWM2OD1zLkWzOVY6KM7:TR?= M{DqUnNCVkeHUh?=
LOUCY NEfFcm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvRSplKSzVyPUGuOVQ3PTdizszN M1OxTHNCVkeHUh?=
SCLC-21H MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XKd2lEPTB;MT61PFU5OiEQvF2= MUPTRW5ITVJ?
TGW MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3POZ2lEPTB;MT62N|k4PSEQvF2= NVPWPFZHW0GQR1XS
LXF-289 NHnse4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTFwN{OyOlgh|ryP MmPHV2FPT0WU
BB49-HNC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTWTWM2OD1zLkezOVg3KM7:TR?= NVmxTFN2W0GQR1XS
NCI-H747 M1jaWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TZcGlEPTB;MT63OVM1PiEQvF2= MlnXV2FPT0WU
LU-165 M{HuW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\YW2dIUUN3ME2xMlg1QTh4IN88US=> NIHwVGVUSU6JRWK=
OMC-1 NILpS2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkniTWM2OD1zLkm1NFY3KM7:TR?= NVHjc|VvW0GQR1XS
RCC10RGB MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\WbXpFUUN3ME2xMlk2QDF5IN88US=> MX7TRW5ITVJ?
SW684 MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVK4PG1TUUN3ME2xMlk3ODl7IN88US=> NWTLfpd7W0GQR1XS
TE-8 M1PWcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnESmZUUUN3ME2yMlA2PTV7IN88US=> MlH2V2FPT0WU
SK-N-DZ NVXLeoNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rM[WlEPTB;Mj6xN|I4PCEQvF2= NWDKXWFUW0GQR1XS
EVSA-T M2LFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4P4RmlEPTB;Mj6xO|MyPSEQvF2= MU\TRW5ITVJ?
KASUMI-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LpfWlEPTB;Mj6xPFgyPSEQvF2= NYO2fW9oW0GQR1XS
NKM-1 MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHCeGpvUUN3ME2yMlI2PDd{IN88US=> MofHV2FPT0WU
CAL-148 NGDGSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXoTWM2OD1{LkOzOlE1KM7:TR?= NIS0cGhUSU6JRWK=
NCI-H64 MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJwM{SyN|Ih|ryP NXLLZ49tW0GQR1XS
KNS-81-FD NH7MVYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLoelFKSzVyPUKuN|Y3OiEQvF2= NWXWV2lbW0GQR1XS
KM12 Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G4UmlEPTB;Mj60NFg{QSEQvF2= M{HzfHNCVkeHUh?=
SW954 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjqUHFPUUN3ME2yMlQ4Pzd7IN88US=> NIDnOHRUSU6JRWK=
NCI-H1395 NHWxcIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTJwNUK2OFUh|ryP MmrlV2FPT0WU
DJM-1 M{n4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTVTWM2OD1{Lk[wOlMh|ryP MU\TRW5ITVJ?
COLO-668 NXj6ZllTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXpXmFKSzVyPUKuPFI3QTVizszN MXvTRW5ITVJ?
NCI-H1436 M{L4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjTR2ZKSzVyPUKuPFU3OTVizszN NELQXXNUSU6JRWK=
LB2241-RCC M1jremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTJwOE[4N|kh|ryP M1fzdHNCVkeHUh?=
GT3TKB M3\xTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2j0fWlEPTB;Mj64PVA2PSEQvF2= MnHNV2FPT0WU
COLO-824 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTsVm9KSzVyPUKuPFk4PjhizszN MXjTRW5ITVJ?
ES1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\0TGlEPTB;Mj64PVg4QSEQvF2= NHm4SnJUSU6JRWK=
LB771-HNC NXzZZmtJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjZS3ZUUUN3ME2yMlkxQTR4IN88US=> M1L5fXNCVkeHUh?=
GI-ME-N NGnCdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmD5TWM2OD1|LkCwPVA1KM7:TR?= NU\tOJdQW0GQR1XS
NALM-6 MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HwWGlEPTB;Mz6wNFk{OyEQvF2= MlviV2FPT0WU
LU-134-A MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq2NYRXUUN3ME2zMlA2PDJ3IN88US=> NI[3XnNUSU6JRWK=
DMS-153 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPUNVZKSzVyPUOuNFU5OjRizszN MkDuV2FPT0WU
MZ1-PC NVjEOGk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3DTWM2OD1|LkC5NFc5KM7:TR?= NHLDWIZUSU6JRWK=
NCI-H1155 MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHoUWVKSzVyPUOuNVE3OSEQvF2= MVjTRW5ITVJ?
CAS-1 MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHe0V41KSzVyPUOuNVM4ODdizszN MWnTRW5ITVJ?
D-502MG M{XzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjsZY5KUUN3ME2zMlE1OzlizszN NI\qe5VUSU6JRWK=
NCI-H2141 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTNwMUe0OVIh|ryP MYrTRW5ITVJ?
NB6 MojBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[0SGlEPTB;Mz6xPFI2QSEQvF2= MV3TRW5ITVJ?
NCCIT MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHWdJdbUUN3ME2zMlIyQDB7IN88US=> NXHjemZSW0GQR1XS
NB69 NEi1N|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TvUGlEPTB;Mz6zNVg6OSEQvF2= M4HNU3NCVkeHUh?=
JVM-2 NWXQVlJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTNwM{[0N|Mh|ryP MULTRW5ITVJ?
K052 M4CxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlj6TWM2OD1|LkO3PVY5KM7:TR?= MULTRW5ITVJ?
HCC2157 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPscXJVUUN3ME2zMlU{OjJ6IN88US=> NXfCO4U1W0GQR1XS
KMOE-2 MljqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHBTm5pUUN3ME2zMlU1OjR{IN88US=> NYrWSVF[W0GQR1XS
SF268 NUfVT2t4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXpVo9KSzVyPUOuO|E2PTRizszN MofhV2FPT0WU
CHP-126 NUPoT4J[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnI[oJKSzVyPUOuO|Y1PThizszN NULze256W0GQR1XS
CP66-MEL MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLT[lRzUUN3ME2zMlc6ODl2IN88US=> NYrF[FY3W0GQR1XS
NCI-H69 NFO5d45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvYTWM2OD12LkCxPVM3KM7:TR?= NH7XW5dUSU6JRWK=
A253 MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7VTWM2OD12LkCyNVAyKM7:TR?= NWTzU3E1W0GQR1XS
NB14 M2nuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTRwMUC0O|kh|ryP Ml7SV2FPT0WU
NCI-H1694 M4DqRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{POXWlEPTB;ND6xN|EyOiEQvF2= NEPoUlhUSU6JRWK=
NCI-H2196 M1HpWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn6NVVwUUN3ME20MlE4OTZ7IN88US=> MkX1V2FPT0WU
TE-9 M2m3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjOWVlWUUN3ME20MlE4PTh{IN88US=> NYC4XmRNW0GQR1XS
D-283MED MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ru[2lEPTB;ND6xPFg1KM7:TR?= M1v0VHNCVkeHUh?=
OCI-AML2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTGdZNKSzVyPUSuNVk1QDlizszN NGLlfINUSU6JRWK=
D-263MG NHvTWGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTRwMkK5OlEh|ryP NFL1clRUSU6JRWK=
MPP-89 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTRwMkezNFQh|ryP MWDTRW5ITVJ?
LAMA-84 MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nHWmlEPTB;ND6zNFQzOSEQvF2= NWG2bmFrW0GQR1XS
LB373-MEL-D M2rKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTRwM{[3PFkh|ryP M3Wyd3NCVkeHUh?=
UACC-257 MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\PTWM2OD12LkO5OVM1KM7:TR?= NVHnXI1WW0GQR1XS
MC-CAR M2nnZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moq5TWM2OD12LkSzPVkh|ryP MU\TRW5ITVJ?
COLO-320-HSR M1vLUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HIR2lEPTB;ND60OFQzPyEQvF2= M2HMe3NCVkeHUh?=
P30-OHK NHPzPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPYOXVKSzVyPUSuOlY2QDFizszN M4rwTXNCVkeHUh?=
UACC-812 NID6Z4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\wemlEPTB;ND62PVE3OSEQvF2= NVPiSINSW0GQR1XS
CTB-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPaTWM2OD12LkexOVU2KM7:TR?= M1\lOnNCVkeHUh?=
ALL-PO M3vBVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LiOGlEPTB;ND64OFA4PyEQvF2= MkW5V2FPT0WU
SK-MEL-2 NYDoRoE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTRwOE[5OVUh|ryP NV2zZXA4W0GQR1XS
TC-YIK NYe3b5dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTRwOUe5OFIh|ryP NEf4V4VUSU6JRWK=
NCI-H1882 NHfibmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHOPZo5UUN3ME21MlAzODBzIN88US=> NFjH[3JUSU6JRWK=
MHH-CALL-2 Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\oTHFCUUN3ME21MlA2ODR{IN88US=> NW\yVphQW0GQR1XS
U-87-MG M17se2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTVwMEm0OlYh|ryP MkLKV2FPT0WU
NCI-H1092 NWD5[5pmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLPTWM2OD13LkK2OVU2KM7:TR?= NXu1ZmFFW0GQR1XS
TE-441-T MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnxfYRKSzVyPUWuNlc5OiEQvF2= NUjYdY1NW0GQR1XS
SK-MEL-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LB[WlEPTB;NT6yPVA1PCEQvF2= MYfTRW5ITVJ?
EW-22 Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[3W4hQUUN3ME21MlI6PDZ4IN88US=> NU\YNGd{W0GQR1XS
MZ7-mel NYH1PZp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnGUnhKSzVyPUWuOFA3QTFizszN NFzSN3RUSU6JRWK=
LP-1 NGWxdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXOTWM2OD13LkSxNlkyKM7:TR?= M2f0e3NCVkeHUh?=
NCI-SNU-16 NF7Ye5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPQZm9IUUN3ME21MlY1ODd2IN88US=> MVrTRW5ITVJ?
LU-65 M2DKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1W3XmlEPTB;NT63OlM4OyEQvF2= MnHwV2FPT0WU
CW-2 M3TseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPxVmdKSzVyPUWuPFU6PTlizszN NEXRRlRUSU6JRWK=
WSU-NHL M33LNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTVwOUWxO|Qh|ryP M2jHc3NCVkeHUh?=
IST-MES1 MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;jbHJKSzVyPUWuPVU1PDNizszN M3\5SnNCVkeHUh?=
U-266 MlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3NS4RKSzVyPUWuPVgzODJizszN NXXhNJJuW0GQR1XS
TALL-1 NHX3bmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTZwMUS2PFgh|ryP MmOzV2FPT0WU
Calu-6 NGX4Om9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnDd5JKSzVyPU[uNVU{OTZizszN MV3TRW5ITVJ?
MMAC-SF NVXve4dVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4KyXmlEPTB;Nj6xPFU2PiEQvF2= MUnTRW5ITVJ?
NCI-H82 NWrGN2J7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTtdm9KSzVyPU[uNlA1QDlizszN Mom3V2FPT0WU
RS4-11 MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnW5TWM2OD14LkK1PFk4KM7:TR?= NF\zW3VUSU6JRWK=
SNU-C2B MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEi1fGdKSzVyPU[uOFA6PjlizszN MojBV2FPT0WU
BOKU MoTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS3TWM2OD14LkS3OVk4KM7:TR?= M3[1XXNCVkeHUh?=
C8166 MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET5XHpKSzVyPU[uOVU6OTJizszN M4HoZnNCVkeHUh?=
D-247MG NFfjVXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXhTVBKSzVyPUeuNFQ{PDdizszN Ml3FV2FPT0WU
EW-18 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\rb2lEPTB;Nz6wO|I6OiEQvF2= MYDTRW5ITVJ?
KG-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTdwNkK3N|gh|ryP Ml3CV2FPT0WU
REH M3rn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\L[mlEPTB;Nz62PFExQSEQvF2= NITNdmhUSU6JRWK=
U-698-M NUHiTHNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TDd2lEPTB;Nz64OFMyPSEQvF2= NXvFT2xGW0GQR1XS
KP-N-RT-BM-1 NG\FRpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTdwOUOwNlkh|ryP M{DGeHNCVkeHUh?=
MS-1 NHPvUWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1v4Z2lEPTB;Nz65OlA1OSEQvF2= MXXTRW5ITVJ?
SNU-C1 NI\Kb5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PzcGlEPTB;Nz65PFE6OiEQvF2= M3fndHNCVkeHUh?=
SK-MM-2 M2jsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHzV2hKSzVyPUiuNlYxPjVizszN NH23OmNUSU6JRWK=
LAN-6 NHLVW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDsTWM2OD16LkOwNFAyKM7:TR?= MX\TRW5ITVJ?
NEC8 NVXOeJJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LFTmlEPTB;OD6zNFY6OSEQvF2= MUfTRW5ITVJ?
NCI-H1770 NYrZc2lET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XPXmlEPTB;OD6zPFAxOiEQvF2= MVzTRW5ITVJ?
D-336MG MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4H0TWlEPTB;OD60NFEyPiEQvF2= MlvoV2FPT0WU
COLO-829 NX;DbJdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zZO2lEPTB;OD60PFg4QSEQvF2= M1vPR3NCVkeHUh?=
LS-513 M1nQTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDDTWM2OD16LkW5OVk6KM7:TR?= M4rvNXNCVkeHUh?=
YT MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\Yd2JKSzVyPUiuOlI1OjdizszN MnrIV2FPT0WU
EW-24 NWSz[mdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfve2pKUUN3ME24Mlc3PTRizszN MmT1V2FPT0WU
IST-SL1 NWrrVplsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[3fGlEPTB;OD64OlU1OyEQvF2= MWHTRW5ITVJ?
CA46 NX36UWRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRThwOUWwPVgh|ryP M1nPcnNCVkeHUh?=
NCI-H1838 NGrMO21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\HNZZKSzVyPUiuPVg3ODJizszN MUPTRW5ITVJ?
NCI-H719 M12zVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPWTWM2OD17LkK1Nlc6KM7:TR?= NVvIUGp[W0GQR1XS
HCE-T Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DYe2lEPTB;OT6zNFg2OSEQvF2= MXjTRW5ITVJ?
A498 NWrVRpJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;CfmRKSzVyPUmuN|YyOjRizszN M{Dhd3NCVkeHUh?=
LB831-BLC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3LfINKSzVyPUmuO|Y2OjFizszN NV\ydWw6W0GQR1XS
SKM-1 NV;qUYdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTlwOEW5OlMh|ryP NWDOVZJ6W0GQR1XS
THP-1 NHPMOZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnLTGNKSzVyPUmuPVY6OThizszN NIS0[XNUSU6JRWK=
SHP-77 M2flbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3hfXJKSzVyPUGwMlQxPyEQvF2= NILnflVUSU6JRWK=
EW-3 NH\SVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlWyTWM2OD1zMD62Nlg6KM7:TR?= NY\PS5NEW0GQR1XS
KY821 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTFyLke2N{DPxE1? NEi4SlJUSU6JRWK=
NCI-SNU-1 M4\NbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYi4[GUzUUN3ME2xNU4xOjF5IN88US=> MXXTRW5ITVJ?
HCC2218 NVzl[3ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\GNGlEPTB;MUGuN|k5PiEQvF2= NUfIeGRJW0GQR1XS
IM-9 MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnG5TWM2OD1zMT61NVA3KM7:TR?= NEHU[2hUSU6JRWK=
NCI-H889 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrZfFhKSzVyPUGxMlU{OTNizszN NHTTcVVUSU6JRWK=
HDLM-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S0T2lEPTB;MUKuOFE2QSEQvF2= M4TJU3NCVkeHUh?=
LB2518-MEL NG\DWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPmdZZlUUN3ME2xNk43QDF3IN88US=> NX6wW49zW0GQR1XS
NCI-H23 NXfk[GdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUWzRnlUUUN3ME2xN{4zPDJ3IN88US=> NH:5T3VUSU6JRWK=
NB17 M4DrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X1XmlEPTB;MUOuOFU4QSEQvF2= MonMV2FPT0WU
NCI-H322M MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3QTWM2OD1zND60NFY5KM7:TR?= M1TyNnNCVkeHUh?=
SUP-T1 NGPFNFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLOVphRUUN3ME2xOE41OTNizszN MULTRW5ITVJ?
ES3 NH71cIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TE[WlEPTB;MUWuNFcxOyEQvF2= NELlUmtUSU6JRWK=
ES5 NVqwOlFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkiyTWM2OD1zNT6wO|g4KM7:TR?= MYjTRW5ITVJ?
NCI-H1650 NHvaVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XsbGlEPTB;MUWuOFk4QSEQvF2= NUDyTVF[W0GQR1XS
NCI-H226 NEHuNGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\GR3dKSzVyPUG1Mlg4PjhizszN NFjmZZRUSU6JRWK=
COR-L88 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofsTWM2OD1zNj6zNVQh|ryP NVzaVHlTW0GQR1XS
SCC-15 NEPMTpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXsNldKSzVyPUG2MlM5PjlizszN NFrHdHNUSU6JRWK=
GOTO NGXsTlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTF4LkS3PVMh|ryP NIeyVWxUSU6JRWK=
SIMA M2G2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\2SHpKSzVyPUG2MlQ5ODJizszN MkLsV2FPT0WU
NCI-H1299 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTF5LkG1PVEh|ryP M{nrTXNCVkeHUh?=
NCI-H1581 Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYr5e4tPUUN3ME2xO{41OjF7IN88US=> MV7TRW5ITVJ?
MHH-NB-11 NU\YfmFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXCTWM2OD1zNz65Olg{KM7:TR?= NEfSeWxUSU6JRWK=
MFM-223 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTF6LkC1N|gh|ryP M3zYZ3NCVkeHUh?=
ES7 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXrVVJKSzVyPUG4MlU1OzFizszN MUTTRW5ITVJ?
JVM-3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\YNmlEPTB;MUiuO|E4KM7:TR?= MnzFV2FPT0WU
RL NIDyb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrhTWM2OD1{MD6zPFgh|ryP NELHc2JUSU6JRWK=
EC-GI-10 M3e4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK1c5VKSzVyPUKxMlIxPDFizszN Mm\1V2FPT0WU
LNCaP-Clone-FGC MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHixenpKSzVyPUKxMlY4PjhizszN MlvHV2FPT0WU
IMR-5 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHj[mVjUUN3ME2yNU45PDl2IN88US=> MoXRV2FPT0WU
KP-N-YS NVXNW4NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXPTWM2OD1{MT64O|Uh|ryP MYPTRW5ITVJ?
Mo-T MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;6TWM2OD1{Mj6yNVg2KM7:TR?= NG[xTHdUSU6JRWK=
NCI-H128 NXPs[WhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJ|LkW4OVMh|ryP MWLTRW5ITVJ?
RH-1 M2e1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[wXWlEPTB;MkOuO|g3PiEQvF2= M1n4eXNCVkeHUh?=
NCI-H2171 NV;aTXRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorETWM2OD1{ND6yOFg2KM7:TR?= NWPXfHk5W0GQR1XS
RPMI-8866 NWnzS2JOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfDcnRKSzVyPUK2Mlc1OiEQvF2= MnX0V2FPT0WU
SK-N-FI NYDuU5U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHWTWM2OD1{Nz6zPFEyKM7:TR?= NETEWJBUSU6JRWK=
LOXIMVI MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLGdHVTUUN3ME2yO{45ODVzIN88US=> MVHTRW5ITVJ?
P31-FUJ MmHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm4TWM2OD1|MT61N|c1KM7:TR?= NXLCOplOW0GQR1XS
KMS-12-PE M3jadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljXTWM2OD12OT61N|AzKM7:TR?= NF36UZlUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]

+ Expand
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
in solvent
Synonyms AY 22989,NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00977691 Active not recruiting Peripheral Blood Stem Cell Transplantation|Anemia Sickle Cell|Graft-Versus-Host Disease|Sirolimus (Rapamune )|Alemtuzumab (Campath ) National Heart Lung and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) September 9 2009 Phase 1|Phase 2
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9 2003 Phase 2
NCT02833506 Withdrawn Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IIA Fallopian Tube Cancer|Stage IIA Ovarian Cancer|Stage IIB Fallopian Tube Cancer|Stage IIB Ovarian Cancer|Stage IIC Fallopian Tube Cancer|Stage IIC Ovarian Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer Roswell Park Cancer Institute|National Cancer Institute (NCI) December 8 2017 Phase 1
NCT01885689 Active not recruiting Adult Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia in Remission|Myelodysplastic Syndrome|Secondary Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Therapy-Related Myelodysplastic Syndrome City of Hope Medical Center|National Cancer Institute (NCI) January 8 2014 Phase 2
NCT01869114 Recruiting Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|de Novo Myelodysplastic Syndromes|Myelodysplastic Syndrome With Isolated Del(5q)|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Myeloid Leukemia Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University July 8 2013 Phase 2
NCT01363752 Completed Kidney Transplantation Astellas Pharma Inc March 8 2011 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID